Cancer chemoresistance: The relationship between p53 and multidrug transporters
Open Access
- 28 February 2002
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 98 (3) , 323-330
- https://doi.org/10.1002/ijc.10226
Abstract
Extensive studies indicate that both p53 and multidrug transporters play important roles in chemoresistance. Since the initial reports a decade ago demonstrating a transcriptional dependence of the ABCB1 gene (MDR) promoter by p53, much data have been accumulated. However, despite being the subject of intense study, this p53‐MDR relationship remains unclear in human cancers. The data are confounded by variable and contrasting results when considering the in vitro regulation and attempting to draw parallels in tissue specimens. The original model suggested that wild‐type p53 downregulates the ABCB1 promoter, whereas mutant p53 increases expression of ABCB1. This review summarizes the data for and against this hypothesis. What emerges from these studies is a complex picture, where data have been obtained in support of this hypothesis, but there are also many circumstances where it is not supported. Taken together, these data suggest that the relationship between p53 and multidrug transporters is conditional. It is dependent on cellular environment, the drug used, and the nature of the p53 mutation.Keywords
This publication has 81 references indexed in Scilit:
- DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1Oncogene, 2001
- Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistanceOncogene, 2001
- Cloning and Initial Analysis of the Human Multidrug Resistance-Related MVP/LRP Gene PromoterBiochemical and Biophysical Research Communications, 2000
- Characterization of 5′-Flanking Region of Human MRP3Biochemical and Biophysical Research Communications, 2000
- The human multidrug resistance protein 2 gene: Functional characterization of the 5′-flanking region and expression in hepatic cellsHepatology, 1999
- Cellular characterisation of p53 mutants with a single missense mutation in the β-strand 326–333 and correlation of their cellular activities with in vitro propertiesJournal of Molecular Biology, 1999
- MDR1 expression correlates with mutantp53 expression in colorectal cancer metastasesZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.Journal of Clinical Pathology, 1996
- The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 ProteinsBiochemical and Biophysical Research Communications, 1995
- Point mutations in the mdr1 promoter of human osteosarcomas are associated with In vitro responsiveness to multidrug resistance relevant drugsEuropean Journal Of Cancer, 1994